<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053222</url>
  </required_header>
  <id_info>
    <org_study_id>11839A</org_study_id>
    <secondary_id>UCCRC-11839A</secondary_id>
    <secondary_id>NCI-5839</secondary_id>
    <nct_id>NCT00053222</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine</brief_title>
  <official_title>A Phase II Study Of Arsenic Trioxide In Patients With Adenocarcinoma Of The Pancreas Refractory To Gemcitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients&#xD;
      who have locally advanced or metastatic pancreatic cancer that has not responded to&#xD;
      gemcitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate to arsenic trioxide in patients with pancreatic&#xD;
           cancer who have progressed after first-line treatment with a gemcitabine-containing&#xD;
           regimen when treated with arsenic trioxide.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the duration of response, median and overall survival, and time to progression&#xD;
           in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive arsenic trioxide IV over 1 hour on days 1-5. Courses repeat every 28 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 9-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arsenic trioxide (0.3 mg/kg/day iv for 5 days every 28 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Unidimensionally measurable disease&#xD;
&#xD;
               -  At least 1 lesion that is at least 20 mm with conventional techniques or at least&#xD;
                  10 mm with spiral CT scan&#xD;
&#xD;
          -  Must have progressed after chemotherapy with a gemcitabine-containing regimen&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  QTc less than 500 msec at baseline by EKG&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart failure&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biological&#xD;
             composition to arsenic trioxide&#xD;
&#xD;
          -  No other active malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent colony-stimulating factors during the first course of the study&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No prior arsenic trioxide&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent therapeutic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational or commercial anticancer agents or therapies&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent antiretroviral therapy in HIV-positive patients&#xD;
&#xD;
          -  No concurrent medications for other comorbid conditions that are known to prolong the&#xD;
             QT interval&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hedy L. Kindler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital Cancer Care Institute</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Health Care - Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LaGrange Memorial Hospital</name>
      <address>
        <city>LaGrange</city>
        <state>Illinois</state>
        <zip>60525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology/Hematology Associates of Central Illinois, P.C.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Illinois Hematology Oncology Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology, Incorporated</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46885-5099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern Indiana CR Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>January 27, 2003</study_first_submitted>
  <study_first_submitted_qc>January 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2003</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

